nodes	percent_of_prediction	percent_of_DWPC	metapath
Paclitaxel—kidney cancer—urinary bladder cancer	0.46	1	CtDrD
Paclitaxel—ABCC10—Gemcitabine—urinary bladder cancer	0.0407	0.129	CbGbCtD
Paclitaxel—ABCC10—Etoposide—urinary bladder cancer	0.029	0.0918	CbGbCtD
Paclitaxel—ABCC10—Doxorubicin—urinary bladder cancer	0.0198	0.0626	CbGbCtD
Paclitaxel—ABCC10—Methotrexate—urinary bladder cancer	0.0192	0.0606	CbGbCtD
Paclitaxel—ABCC1—Epirubicin—urinary bladder cancer	0.0144	0.0455	CbGbCtD
Paclitaxel—ABCB1—Mitomycin—urinary bladder cancer	0.0132	0.0416	CbGbCtD
Paclitaxel—ABCC1—Etoposide—urinary bladder cancer	0.0112	0.0354	CbGbCtD
Paclitaxel—ABCB11—Doxorubicin—urinary bladder cancer	0.0108	0.034	CbGbCtD
Paclitaxel—CYP1B1—Doxorubicin—urinary bladder cancer	0.0108	0.034	CbGbCtD
Paclitaxel—SLCO1B3—Methotrexate—urinary bladder cancer	0.0107	0.0339	CbGbCtD
Paclitaxel—ABCC2—Carboplatin—urinary bladder cancer	0.00988	0.0312	CbGbCtD
Paclitaxel—ABCG2—Fluorouracil—urinary bladder cancer	0.00899	0.0284	CbGbCtD
Paclitaxel—ABCG2—Carboplatin—urinary bladder cancer	0.00893	0.0282	CbGbCtD
Paclitaxel—ABCC2—Cisplatin—urinary bladder cancer	0.00844	0.0267	CbGbCtD
Paclitaxel—ABCC2—Etoposide—urinary bladder cancer	0.0083	0.0262	CbGbCtD
Paclitaxel—ABCC1—Doxorubicin—urinary bladder cancer	0.00765	0.0242	CbGbCtD
Paclitaxel—ABCG2—Cisplatin—urinary bladder cancer	0.00763	0.0241	CbGbCtD
Paclitaxel—ABCG2—Etoposide—urinary bladder cancer	0.0075	0.0237	CbGbCtD
Paclitaxel—ABCC1—Methotrexate—urinary bladder cancer	0.00741	0.0234	CbGbCtD
Paclitaxel—CYP3A4—Thiotepa—urinary bladder cancer	0.00598	0.0189	CbGbCtD
Paclitaxel—ABCC2—Doxorubicin—urinary bladder cancer	0.00566	0.0179	CbGbCtD
Paclitaxel—ABCC2—Methotrexate—urinary bladder cancer	0.00548	0.0173	CbGbCtD
Paclitaxel—ABCG2—Doxorubicin—urinary bladder cancer	0.00512	0.0162	CbGbCtD
Paclitaxel—ABCG2—Methotrexate—urinary bladder cancer	0.00496	0.0157	CbGbCtD
Paclitaxel—CYP2C8—Fluorouracil—urinary bladder cancer	0.00479	0.0151	CbGbCtD
Paclitaxel—CYP3A5—Etoposide—urinary bladder cancer	0.00416	0.0131	CbGbCtD
Paclitaxel—CYP2C8—Etoposide—urinary bladder cancer	0.004	0.0126	CbGbCtD
Paclitaxel—ABCB1—Gemcitabine—urinary bladder cancer	0.00379	0.012	CbGbCtD
Paclitaxel—CYP2C9—Fluorouracil—urinary bladder cancer	0.00334	0.0106	CbGbCtD
Paclitaxel—CYP2C9—Cisplatin—urinary bladder cancer	0.00284	0.00896	CbGbCtD
Paclitaxel—ABCB1—Cisplatin—urinary bladder cancer	0.00275	0.0087	CbGbCtD
Paclitaxel—ABCB1—Etoposide—urinary bladder cancer	0.0027	0.00855	CbGbCtD
Paclitaxel—ABCB1—Doxorubicin—urinary bladder cancer	0.00184	0.00583	CbGbCtD
Paclitaxel—ABCB1—Methotrexate—urinary bladder cancer	0.00179	0.00565	CbGbCtD
Paclitaxel—CYP3A4—Etoposide—urinary bladder cancer	0.00162	0.00512	CbGbCtD
Paclitaxel—MAPT—prostate gland—urinary bladder cancer	0.00146	0.0342	CbGeAlD
Paclitaxel—MAP4—prostate gland—urinary bladder cancer	0.00115	0.0269	CbGeAlD
Paclitaxel—CYP3A4—Doxorubicin—urinary bladder cancer	0.00111	0.00349	CbGbCtD
Paclitaxel—BCL2—prostate gland—urinary bladder cancer	0.00104	0.0244	CbGeAlD
Paclitaxel—Docetaxel—EGFR—urinary bladder cancer	0.00103	1	CrCbGaD
Paclitaxel—MAP2—prostate gland—urinary bladder cancer	0.000902	0.0212	CbGeAlD
Paclitaxel—CYP2C9—urine—urinary bladder cancer	0.000816	0.0191	CbGeAlD
Paclitaxel—MAP4—renal system—urinary bladder cancer	0.000781	0.0183	CbGeAlD
Paclitaxel—BCL2—epithelium—urinary bladder cancer	0.000765	0.0179	CbGeAlD
Paclitaxel—MAP2—seminal vesicle—urinary bladder cancer	0.000763	0.0179	CbGeAlD
Paclitaxel—TUBB6—Zalcitabine—Gemcitabine—urinary bladder cancer	0.000753	0.582	CbGdCrCtD
Paclitaxel—BCL2—smooth muscle tissue—urinary bladder cancer	0.000737	0.0173	CbGeAlD
Paclitaxel—BCL2—renal system—urinary bladder cancer	0.00071	0.0166	CbGeAlD
Paclitaxel—TUBB4A—prostate gland—urinary bladder cancer	0.000697	0.0163	CbGeAlD
Paclitaxel—TUBB2B—prostate gland—urinary bladder cancer	0.000674	0.0158	CbGeAlD
Paclitaxel—TUBB—prostate gland—urinary bladder cancer	0.000638	0.015	CbGeAlD
Paclitaxel—TUBB2A—prostate gland—urinary bladder cancer	0.000634	0.0149	CbGeAlD
Paclitaxel—TUBB6—prostate gland—urinary bladder cancer	0.000626	0.0147	CbGeAlD
Paclitaxel—MAP4—female reproductive system—urinary bladder cancer	0.000625	0.0147	CbGeAlD
Paclitaxel—CYP3A4—urine—urinary bladder cancer	0.000622	0.0146	CbGeAlD
Paclitaxel—MAP2—urethra—urinary bladder cancer	0.000604	0.0142	CbGeAlD
Paclitaxel—TUBB2B—seminal vesicle—urinary bladder cancer	0.00057	0.0134	CbGeAlD
Paclitaxel—BCL2—female reproductive system—urinary bladder cancer	0.000568	0.0133	CbGeAlD
Paclitaxel—MAP4—vagina—urinary bladder cancer	0.000566	0.0133	CbGeAlD
Paclitaxel—ABCC10—prostate gland—urinary bladder cancer	0.000548	0.0128	CbGeAlD
Paclitaxel—TUBB4B—prostate gland—urinary bladder cancer	0.000544	0.0127	CbGeAlD
Paclitaxel—TUBB—seminal vesicle—urinary bladder cancer	0.000539	0.0126	CbGeAlD
Paclitaxel—TUBB2A—seminal vesicle—urinary bladder cancer	0.000536	0.0126	CbGeAlD
Paclitaxel—TUBB6—seminal vesicle—urinary bladder cancer	0.000529	0.0124	CbGeAlD
Paclitaxel—SLCO1B3—vagina—urinary bladder cancer	0.000495	0.0116	CbGeAlD
Paclitaxel—MAP2—female reproductive system—urinary bladder cancer	0.000492	0.0115	CbGeAlD
Paclitaxel—TUBB4A—renal system—urinary bladder cancer	0.000475	0.0111	CbGeAlD
Paclitaxel—MAPT—lymph node—urinary bladder cancer	0.000465	0.0109	CbGeAlD
Paclitaxel—ABCC10—seminal vesicle—urinary bladder cancer	0.000463	0.0109	CbGeAlD
Paclitaxel—CYP19A1—prostate gland—urinary bladder cancer	0.000461	0.0108	CbGeAlD
Paclitaxel—TUBB4B—seminal vesicle—urinary bladder cancer	0.00046	0.0108	CbGeAlD
Paclitaxel—TUBB6—epithelium—urinary bladder cancer	0.00046	0.0108	CbGeAlD
Paclitaxel—TUBB2B—renal system—urinary bladder cancer	0.000459	0.0108	CbGeAlD
Paclitaxel—TUBB—smooth muscle tissue—urinary bladder cancer	0.000451	0.0106	CbGeAlD
Paclitaxel—TUBB2B—urethra—urinary bladder cancer	0.000451	0.0106	CbGeAlD
Paclitaxel—TUBB2A—smooth muscle tissue—urinary bladder cancer	0.000449	0.0105	CbGeAlD
Paclitaxel—MAP2—vagina—urinary bladder cancer	0.000445	0.0104	CbGeAlD
Paclitaxel—TUBB6—smooth muscle tissue—urinary bladder cancer	0.000443	0.0104	CbGeAlD
Paclitaxel—ABCC2—prostate gland—urinary bladder cancer	0.00044	0.0103	CbGeAlD
Paclitaxel—CYP1B1—prostate gland—urinary bladder cancer	0.000431	0.0101	CbGeAlD
Paclitaxel—TUBB—urethra—urinary bladder cancer	0.000427	0.01	CbGeAlD
Paclitaxel—TUBB6—renal system—urinary bladder cancer	0.000426	0.01	CbGeAlD
Paclitaxel—TUBB2A—urethra—urinary bladder cancer	0.000425	0.00996	CbGeAlD
Paclitaxel—TUBB6—urethra—urinary bladder cancer	0.000419	0.00982	CbGeAlD
Paclitaxel—ABCC1—prostate gland—urinary bladder cancer	0.000387	0.00908	CbGeAlD
Paclitaxel—TUBB4B—smooth muscle tissue—urinary bladder cancer	0.000385	0.00903	CbGeAlD
Paclitaxel—TUBB—Azacitidine—Gemcitabine—urinary bladder cancer	0.000383	0.296	CbGdCrCtD
Paclitaxel—TUBB4A—female reproductive system—urinary bladder cancer	0.000381	0.00892	CbGeAlD
Paclitaxel—ABCC10—renal system—urinary bladder cancer	0.000373	0.00875	CbGeAlD
Paclitaxel—TUBB4B—renal system—urinary bladder cancer	0.000371	0.00869	CbGeAlD
Paclitaxel—TUBB2B—female reproductive system—urinary bladder cancer	0.000368	0.00862	CbGeAlD
Paclitaxel—ABCC10—urethra—urinary bladder cancer	0.000367	0.0086	CbGeAlD
Paclitaxel—MAP4—lymph node—urinary bladder cancer	0.000366	0.00858	CbGeAlD
Paclitaxel—TUBB4B—urethra—urinary bladder cancer	0.000364	0.00854	CbGeAlD
Paclitaxel—TUBB2A—female reproductive system—urinary bladder cancer	0.000346	0.00812	CbGeAlD
Paclitaxel—TUBB6—female reproductive system—urinary bladder cancer	0.000341	0.00801	CbGeAlD
Paclitaxel—TUBB2B—vagina—urinary bladder cancer	0.000333	0.0078	CbGeAlD
Paclitaxel—BCL2—lymph node—urinary bladder cancer	0.000333	0.0078	CbGeAlD
Paclitaxel—ABCC1—seminal vesicle—urinary bladder cancer	0.000328	0.00768	CbGeAlD
Paclitaxel—ABCG2—prostate gland—urinary bladder cancer	0.000321	0.00752	CbGeAlD
Paclitaxel—TUBB—vagina—urinary bladder cancer	0.000315	0.00738	CbGeAlD
Paclitaxel—TUBB2A—vagina—urinary bladder cancer	0.000313	0.00734	CbGeAlD
Paclitaxel—TUBB6—vagina—urinary bladder cancer	0.000309	0.00724	CbGeAlD
Paclitaxel—CYP1B1—smooth muscle tissue—urinary bladder cancer	0.000305	0.00715	CbGeAlD
Paclitaxel—ABCC2—renal system—urinary bladder cancer	0.0003	0.00703	CbGeAlD
Paclitaxel—ABCC10—female reproductive system—urinary bladder cancer	0.000299	0.00701	CbGeAlD
Paclitaxel—CYP3A5—prostate gland—urinary bladder cancer	0.000298	0.00698	CbGeAlD
Paclitaxel—TUBB4B—female reproductive system—urinary bladder cancer	0.000297	0.00696	CbGeAlD
Paclitaxel—CYP1B1—renal system—urinary bladder cancer	0.000294	0.00688	CbGeAlD
Paclitaxel—MAP2—lymph node—urinary bladder cancer	0.000288	0.00675	CbGeAlD
Paclitaxel—ABCG2—seminal vesicle—urinary bladder cancer	0.000271	0.00636	CbGeAlD
Paclitaxel—ABCC10—vagina—urinary bladder cancer	0.00027	0.00634	CbGeAlD
Paclitaxel—TUBB4B—vagina—urinary bladder cancer	0.000268	0.00629	CbGeAlD
Paclitaxel—ABCC1—urethra—urinary bladder cancer	0.000259	0.00608	CbGeAlD
Paclitaxel—CYP19A1—female reproductive system—urinary bladder cancer	0.000252	0.0059	CbGeAlD
Paclitaxel—ABCC2—female reproductive system—urinary bladder cancer	0.00024	0.00563	CbGeAlD
Paclitaxel—CYP1B1—female reproductive system—urinary bladder cancer	0.000235	0.00551	CbGeAlD
Paclitaxel—CYP2C8—renal system—urinary bladder cancer	0.000225	0.00527	CbGeAlD
Paclitaxel—TUBB4A—lymph node—urinary bladder cancer	0.000223	0.00522	CbGeAlD
Paclitaxel—TUBB2B—lymph node—urinary bladder cancer	0.000215	0.00504	CbGeAlD
Paclitaxel—ABCG2—urethra—urinary bladder cancer	0.000215	0.00503	CbGeAlD
Paclitaxel—TUBB—lymph node—urinary bladder cancer	0.000204	0.00477	CbGeAlD
Paclitaxel—CYP3A5—renal system—urinary bladder cancer	0.000203	0.00476	CbGeAlD
Paclitaxel—TUBB2A—lymph node—urinary bladder cancer	0.000203	0.00475	CbGeAlD
Paclitaxel—TUBB6—lymph node—urinary bladder cancer	0.0002	0.00468	CbGeAlD
Paclitaxel—ABCC1—vagina—urinary bladder cancer	0.000191	0.00448	CbGeAlD
Paclitaxel—CYP2C8—female reproductive system—urinary bladder cancer	0.00018	0.00422	CbGeAlD
Paclitaxel—ABCC10—lymph node—urinary bladder cancer	0.000175	0.0041	CbGeAlD
Paclitaxel—TUBB4B—lymph node—urinary bladder cancer	0.000174	0.00407	CbGeAlD
Paclitaxel—CYP2C8—vagina—urinary bladder cancer	0.000163	0.00382	CbGeAlD
Paclitaxel—CYP2C9—female reproductive system—urinary bladder cancer	0.00016	0.00375	CbGeAlD
Paclitaxel—ABCG2—vagina—urinary bladder cancer	0.000158	0.00371	CbGeAlD
Paclitaxel—TUBB6—Azacitidine—Gemcitabine—urinary bladder cancer	0.000158	0.122	CbGdCrCtD
Paclitaxel—ABCB1—prostate gland—urinary bladder cancer	0.000158	0.00371	CbGeAlD
Paclitaxel—CYP3A4—renal system—urinary bladder cancer	0.000152	0.00357	CbGeAlD
Paclitaxel—CYP19A1—lymph node—urinary bladder cancer	0.000147	0.00345	CbGeAlD
Paclitaxel—CYP3A5—vagina—urinary bladder cancer	0.000147	0.00345	CbGeAlD
Paclitaxel—ABCC2—lymph node—urinary bladder cancer	0.00014	0.00329	CbGeAlD
Paclitaxel—CYP1B1—lymph node—urinary bladder cancer	0.000138	0.00322	CbGeAlD
Paclitaxel—ABCB1—seminal vesicle—urinary bladder cancer	0.000134	0.00314	CbGeAlD
Paclitaxel—ABCC1—lymph node—urinary bladder cancer	0.000124	0.0029	CbGeAlD
Paclitaxel—CYP3A4—female reproductive system—urinary bladder cancer	0.000122	0.00286	CbGeAlD
Paclitaxel—ABCB1—epithelium—urinary bladder cancer	0.000116	0.00272	CbGeAlD
Paclitaxel—ABCB1—renal system—urinary bladder cancer	0.000108	0.00253	CbGeAlD
Paclitaxel—ABCB1—urethra—urinary bladder cancer	0.000106	0.00248	CbGeAlD
Paclitaxel—ABCG2—lymph node—urinary bladder cancer	0.000102	0.0024	CbGeAlD
Paclitaxel—ABCB1—female reproductive system—urinary bladder cancer	8.63e-05	0.00202	CbGeAlD
Paclitaxel—ABCB1—vagina—urinary bladder cancer	7.81e-05	0.00183	CbGeAlD
Paclitaxel—ABCB1—lymph node—urinary bladder cancer	5.05e-05	0.00118	CbGeAlD
Paclitaxel—Immune system disorder—Methotrexate—urinary bladder cancer	2.64e-05	0.000229	CcSEcCtD
Paclitaxel—Dizziness—Fluorouracil—urinary bladder cancer	2.64e-05	0.000229	CcSEcCtD
Paclitaxel—Visual impairment—Epirubicin—urinary bladder cancer	2.64e-05	0.000228	CcSEcCtD
Paclitaxel—Mediastinal disorder—Methotrexate—urinary bladder cancer	2.64e-05	0.000228	CcSEcCtD
Paclitaxel—Chills—Methotrexate—urinary bladder cancer	2.62e-05	0.000227	CcSEcCtD
Paclitaxel—Diarrhoea—Cisplatin—urinary bladder cancer	2.59e-05	0.000224	CcSEcCtD
Paclitaxel—Erythema multiforme—Epirubicin—urinary bladder cancer	2.59e-05	0.000224	CcSEcCtD
Paclitaxel—Alopecia—Methotrexate—urinary bladder cancer	2.58e-05	0.000224	CcSEcCtD
Paclitaxel—Vomiting—Gemcitabine—urinary bladder cancer	2.58e-05	0.000224	CcSEcCtD
Paclitaxel—Bradycardia—Doxorubicin—urinary bladder cancer	2.58e-05	0.000223	CcSEcCtD
Paclitaxel—Mental disorder—Methotrexate—urinary bladder cancer	2.56e-05	0.000222	CcSEcCtD
Paclitaxel—Rash—Gemcitabine—urinary bladder cancer	2.56e-05	0.000222	CcSEcCtD
Paclitaxel—Dermatitis—Gemcitabine—urinary bladder cancer	2.56e-05	0.000222	CcSEcCtD
Paclitaxel—Eye disorder—Epirubicin—urinary bladder cancer	2.56e-05	0.000222	CcSEcCtD
Paclitaxel—Hypersensitivity—Etoposide—urinary bladder cancer	2.56e-05	0.000221	CcSEcCtD
Paclitaxel—Tinnitus—Epirubicin—urinary bladder cancer	2.55e-05	0.000221	CcSEcCtD
Paclitaxel—Erythema—Methotrexate—urinary bladder cancer	2.55e-05	0.00022	CcSEcCtD
Paclitaxel—Malnutrition—Methotrexate—urinary bladder cancer	2.55e-05	0.00022	CcSEcCtD
Paclitaxel—Haemoglobin—Doxorubicin—urinary bladder cancer	2.55e-05	0.00022	CcSEcCtD
Paclitaxel—Headache—Gemcitabine—urinary bladder cancer	2.55e-05	0.00022	CcSEcCtD
Paclitaxel—Flushing—Epirubicin—urinary bladder cancer	2.54e-05	0.00022	CcSEcCtD
Paclitaxel—Cardiac disorder—Epirubicin—urinary bladder cancer	2.54e-05	0.00022	CcSEcCtD
Paclitaxel—Vomiting—Fluorouracil—urinary bladder cancer	2.54e-05	0.00022	CcSEcCtD
Paclitaxel—Rhinitis—Doxorubicin—urinary bladder cancer	2.54e-05	0.00022	CcSEcCtD
Paclitaxel—Haemorrhage—Doxorubicin—urinary bladder cancer	2.53e-05	0.000219	CcSEcCtD
Paclitaxel—Hypoaesthesia—Doxorubicin—urinary bladder cancer	2.52e-05	0.000218	CcSEcCtD
Paclitaxel—Rash—Fluorouracil—urinary bladder cancer	2.52e-05	0.000218	CcSEcCtD
Paclitaxel—Dermatitis—Fluorouracil—urinary bladder cancer	2.52e-05	0.000218	CcSEcCtD
Paclitaxel—Pharyngitis—Doxorubicin—urinary bladder cancer	2.51e-05	0.000218	CcSEcCtD
Paclitaxel—Headache—Fluorouracil—urinary bladder cancer	2.5e-05	0.000217	CcSEcCtD
Paclitaxel—Urinary tract disorder—Doxorubicin—urinary bladder cancer	2.5e-05	0.000217	CcSEcCtD
Paclitaxel—Oedema peripheral—Doxorubicin—urinary bladder cancer	2.5e-05	0.000216	CcSEcCtD
Paclitaxel—Dysgeusia—Methotrexate—urinary bladder cancer	2.49e-05	0.000216	CcSEcCtD
Paclitaxel—Asthenia—Etoposide—urinary bladder cancer	2.49e-05	0.000216	CcSEcCtD
Paclitaxel—Connective tissue disorder—Doxorubicin—urinary bladder cancer	2.49e-05	0.000216	CcSEcCtD
Paclitaxel—Angiopathy—Epirubicin—urinary bladder cancer	2.48e-05	0.000215	CcSEcCtD
Paclitaxel—Urethral disorder—Doxorubicin—urinary bladder cancer	2.48e-05	0.000215	CcSEcCtD
Paclitaxel—Immune system disorder—Epirubicin—urinary bladder cancer	2.47e-05	0.000214	CcSEcCtD
Paclitaxel—Mediastinal disorder—Epirubicin—urinary bladder cancer	2.47e-05	0.000214	CcSEcCtD
Paclitaxel—Back pain—Methotrexate—urinary bladder cancer	2.46e-05	0.000213	CcSEcCtD
Paclitaxel—Chills—Epirubicin—urinary bladder cancer	2.46e-05	0.000213	CcSEcCtD
Paclitaxel—Pruritus—Etoposide—urinary bladder cancer	2.45e-05	0.000213	CcSEcCtD
Paclitaxel—Arrhythmia—Epirubicin—urinary bladder cancer	2.45e-05	0.000212	CcSEcCtD
Paclitaxel—Visual impairment—Doxorubicin—urinary bladder cancer	2.44e-05	0.000211	CcSEcCtD
Paclitaxel—Alopecia—Epirubicin—urinary bladder cancer	2.42e-05	0.000209	CcSEcCtD
Paclitaxel—Nausea—Gemcitabine—urinary bladder cancer	2.41e-05	0.000209	CcSEcCtD
Paclitaxel—Vomiting—Cisplatin—urinary bladder cancer	2.41e-05	0.000209	CcSEcCtD
Paclitaxel—Vision blurred—Methotrexate—urinary bladder cancer	2.4e-05	0.000208	CcSEcCtD
Paclitaxel—Mental disorder—Epirubicin—urinary bladder cancer	2.4e-05	0.000208	CcSEcCtD
Paclitaxel—Erythema multiforme—Doxorubicin—urinary bladder cancer	2.39e-05	0.000207	CcSEcCtD
Paclitaxel—Rash—Cisplatin—urinary bladder cancer	2.39e-05	0.000207	CcSEcCtD
Paclitaxel—Dermatitis—Cisplatin—urinary bladder cancer	2.39e-05	0.000207	CcSEcCtD
Paclitaxel—Malnutrition—Epirubicin—urinary bladder cancer	2.38e-05	0.000206	CcSEcCtD
Paclitaxel—Erythema—Epirubicin—urinary bladder cancer	2.38e-05	0.000206	CcSEcCtD
Paclitaxel—Diarrhoea—Etoposide—urinary bladder cancer	2.37e-05	0.000206	CcSEcCtD
Paclitaxel—Nausea—Fluorouracil—urinary bladder cancer	2.37e-05	0.000205	CcSEcCtD
Paclitaxel—Eye disorder—Doxorubicin—urinary bladder cancer	2.37e-05	0.000205	CcSEcCtD
Paclitaxel—Ill-defined disorder—Methotrexate—urinary bladder cancer	2.36e-05	0.000205	CcSEcCtD
Paclitaxel—Tinnitus—Doxorubicin—urinary bladder cancer	2.36e-05	0.000204	CcSEcCtD
Paclitaxel—Anaemia—Methotrexate—urinary bladder cancer	2.35e-05	0.000204	CcSEcCtD
Paclitaxel—Flushing—Doxorubicin—urinary bladder cancer	2.35e-05	0.000204	CcSEcCtD
Paclitaxel—Cardiac disorder—Doxorubicin—urinary bladder cancer	2.35e-05	0.000204	CcSEcCtD
Paclitaxel—Flatulence—Epirubicin—urinary bladder cancer	2.35e-05	0.000203	CcSEcCtD
Paclitaxel—Tension—Epirubicin—urinary bladder cancer	2.34e-05	0.000202	CcSEcCtD
Paclitaxel—Dysgeusia—Epirubicin—urinary bladder cancer	2.33e-05	0.000202	CcSEcCtD
Paclitaxel—Nervousness—Epirubicin—urinary bladder cancer	2.31e-05	0.0002	CcSEcCtD
Paclitaxel—Back pain—Epirubicin—urinary bladder cancer	2.3e-05	0.0002	CcSEcCtD
Paclitaxel—Angiopathy—Doxorubicin—urinary bladder cancer	2.3e-05	0.000199	CcSEcCtD
Paclitaxel—Malaise—Methotrexate—urinary bladder cancer	2.3e-05	0.000199	CcSEcCtD
Paclitaxel—Dizziness—Etoposide—urinary bladder cancer	2.29e-05	0.000199	CcSEcCtD
Paclitaxel—Muscle spasms—Epirubicin—urinary bladder cancer	2.29e-05	0.000198	CcSEcCtD
Paclitaxel—Immune system disorder—Doxorubicin—urinary bladder cancer	2.29e-05	0.000198	CcSEcCtD
Paclitaxel—Vertigo—Methotrexate—urinary bladder cancer	2.29e-05	0.000198	CcSEcCtD
Paclitaxel—Mediastinal disorder—Doxorubicin—urinary bladder cancer	2.28e-05	0.000198	CcSEcCtD
Paclitaxel—Leukopenia—Methotrexate—urinary bladder cancer	2.28e-05	0.000197	CcSEcCtD
Paclitaxel—Chills—Doxorubicin—urinary bladder cancer	2.27e-05	0.000197	CcSEcCtD
Paclitaxel—Arrhythmia—Doxorubicin—urinary bladder cancer	2.26e-05	0.000196	CcSEcCtD
Paclitaxel—Nausea—Cisplatin—urinary bladder cancer	2.25e-05	0.000195	CcSEcCtD
Paclitaxel—Vision blurred—Epirubicin—urinary bladder cancer	2.25e-05	0.000194	CcSEcCtD
Paclitaxel—Alopecia—Doxorubicin—urinary bladder cancer	2.24e-05	0.000194	CcSEcCtD
Paclitaxel—Cough—Methotrexate—urinary bladder cancer	2.22e-05	0.000192	CcSEcCtD
Paclitaxel—Mental disorder—Doxorubicin—urinary bladder cancer	2.22e-05	0.000192	CcSEcCtD
Paclitaxel—Ill-defined disorder—Epirubicin—urinary bladder cancer	2.21e-05	0.000191	CcSEcCtD
Paclitaxel—Convulsion—Methotrexate—urinary bladder cancer	2.21e-05	0.000191	CcSEcCtD
Paclitaxel—Vomiting—Etoposide—urinary bladder cancer	2.21e-05	0.000191	CcSEcCtD
Paclitaxel—Malnutrition—Doxorubicin—urinary bladder cancer	2.2e-05	0.000191	CcSEcCtD
Paclitaxel—Erythema—Doxorubicin—urinary bladder cancer	2.2e-05	0.000191	CcSEcCtD
Paclitaxel—Anaemia—Epirubicin—urinary bladder cancer	2.2e-05	0.000191	CcSEcCtD
Paclitaxel—Agitation—Epirubicin—urinary bladder cancer	2.19e-05	0.00019	CcSEcCtD
Paclitaxel—Rash—Etoposide—urinary bladder cancer	2.19e-05	0.000189	CcSEcCtD
Paclitaxel—Dermatitis—Etoposide—urinary bladder cancer	2.19e-05	0.000189	CcSEcCtD
Paclitaxel—Headache—Etoposide—urinary bladder cancer	2.17e-05	0.000188	CcSEcCtD
Paclitaxel—Flatulence—Doxorubicin—urinary bladder cancer	2.17e-05	0.000188	CcSEcCtD
Paclitaxel—Chest pain—Methotrexate—urinary bladder cancer	2.17e-05	0.000188	CcSEcCtD
Paclitaxel—Arthralgia—Methotrexate—urinary bladder cancer	2.17e-05	0.000188	CcSEcCtD
Paclitaxel—Myalgia—Methotrexate—urinary bladder cancer	2.17e-05	0.000188	CcSEcCtD
Paclitaxel—Tension—Doxorubicin—urinary bladder cancer	2.16e-05	0.000187	CcSEcCtD
Paclitaxel—Dysgeusia—Doxorubicin—urinary bladder cancer	2.16e-05	0.000187	CcSEcCtD
Paclitaxel—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	2.15e-05	0.000186	CcSEcCtD
Paclitaxel—Malaise—Epirubicin—urinary bladder cancer	2.15e-05	0.000186	CcSEcCtD
Paclitaxel—Discomfort—Methotrexate—urinary bladder cancer	2.14e-05	0.000185	CcSEcCtD
Paclitaxel—Nervousness—Doxorubicin—urinary bladder cancer	2.14e-05	0.000185	CcSEcCtD
Paclitaxel—Vertigo—Epirubicin—urinary bladder cancer	2.14e-05	0.000185	CcSEcCtD
Paclitaxel—Syncope—Epirubicin—urinary bladder cancer	2.14e-05	0.000185	CcSEcCtD
Paclitaxel—Leukopenia—Epirubicin—urinary bladder cancer	2.13e-05	0.000185	CcSEcCtD
Paclitaxel—Back pain—Doxorubicin—urinary bladder cancer	2.13e-05	0.000185	CcSEcCtD
Paclitaxel—Muscle spasms—Doxorubicin—urinary bladder cancer	2.12e-05	0.000184	CcSEcCtD
Paclitaxel—Palpitations—Epirubicin—urinary bladder cancer	2.11e-05	0.000182	CcSEcCtD
Paclitaxel—Confusional state—Methotrexate—urinary bladder cancer	2.1e-05	0.000181	CcSEcCtD
Paclitaxel—Loss of consciousness—Epirubicin—urinary bladder cancer	2.09e-05	0.000181	CcSEcCtD
Paclitaxel—Cough—Epirubicin—urinary bladder cancer	2.08e-05	0.00018	CcSEcCtD
Paclitaxel—Anaphylactic shock—Methotrexate—urinary bladder cancer	2.08e-05	0.00018	CcSEcCtD
Paclitaxel—Vision blurred—Doxorubicin—urinary bladder cancer	2.08e-05	0.00018	CcSEcCtD
Paclitaxel—Convulsion—Epirubicin—urinary bladder cancer	2.06e-05	0.000179	CcSEcCtD
Paclitaxel—Infection—Methotrexate—urinary bladder cancer	2.06e-05	0.000179	CcSEcCtD
Paclitaxel—Nausea—Etoposide—urinary bladder cancer	2.06e-05	0.000178	CcSEcCtD
Paclitaxel—Hypertension—Epirubicin—urinary bladder cancer	2.06e-05	0.000178	CcSEcCtD
Paclitaxel—Ill-defined disorder—Doxorubicin—urinary bladder cancer	2.05e-05	0.000177	CcSEcCtD
Paclitaxel—Nervous system disorder—Methotrexate—urinary bladder cancer	2.04e-05	0.000176	CcSEcCtD
Paclitaxel—Anaemia—Doxorubicin—urinary bladder cancer	2.04e-05	0.000176	CcSEcCtD
Paclitaxel—Thrombocytopenia—Methotrexate—urinary bladder cancer	2.03e-05	0.000176	CcSEcCtD
Paclitaxel—Chest pain—Epirubicin—urinary bladder cancer	2.03e-05	0.000176	CcSEcCtD
Paclitaxel—Arthralgia—Epirubicin—urinary bladder cancer	2.03e-05	0.000176	CcSEcCtD
Paclitaxel—Myalgia—Epirubicin—urinary bladder cancer	2.03e-05	0.000176	CcSEcCtD
Paclitaxel—Agitation—Doxorubicin—urinary bladder cancer	2.03e-05	0.000175	CcSEcCtD
Paclitaxel—Anxiety—Epirubicin—urinary bladder cancer	2.02e-05	0.000175	CcSEcCtD
Paclitaxel—Skin disorder—Methotrexate—urinary bladder cancer	2.02e-05	0.000175	CcSEcCtD
Paclitaxel—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	2.01e-05	0.000174	CcSEcCtD
Paclitaxel—Hyperhidrosis—Methotrexate—urinary bladder cancer	2.01e-05	0.000174	CcSEcCtD
Paclitaxel—Discomfort—Epirubicin—urinary bladder cancer	2e-05	0.000174	CcSEcCtD
Paclitaxel—Malaise—Doxorubicin—urinary bladder cancer	1.99e-05	0.000172	CcSEcCtD
Paclitaxel—Dry mouth—Epirubicin—urinary bladder cancer	1.98e-05	0.000172	CcSEcCtD
Paclitaxel—Vertigo—Doxorubicin—urinary bladder cancer	1.98e-05	0.000172	CcSEcCtD
Paclitaxel—Anorexia—Methotrexate—urinary bladder cancer	1.98e-05	0.000172	CcSEcCtD
Paclitaxel—Syncope—Doxorubicin—urinary bladder cancer	1.98e-05	0.000171	CcSEcCtD
Paclitaxel—Leukopenia—Doxorubicin—urinary bladder cancer	1.97e-05	0.000171	CcSEcCtD
Paclitaxel—Confusional state—Epirubicin—urinary bladder cancer	1.96e-05	0.00017	CcSEcCtD
Paclitaxel—Palpitations—Doxorubicin—urinary bladder cancer	1.95e-05	0.000169	CcSEcCtD
Paclitaxel—Anaphylactic shock—Epirubicin—urinary bladder cancer	1.94e-05	0.000168	CcSEcCtD
Paclitaxel—Oedema—Epirubicin—urinary bladder cancer	1.94e-05	0.000168	CcSEcCtD
Paclitaxel—Hypotension—Methotrexate—urinary bladder cancer	1.94e-05	0.000168	CcSEcCtD
Paclitaxel—Loss of consciousness—Doxorubicin—urinary bladder cancer	1.94e-05	0.000168	CcSEcCtD
Paclitaxel—Infection—Epirubicin—urinary bladder cancer	1.93e-05	0.000167	CcSEcCtD
Paclitaxel—Cough—Doxorubicin—urinary bladder cancer	1.92e-05	0.000167	CcSEcCtD
Paclitaxel—Shock—Epirubicin—urinary bladder cancer	1.91e-05	0.000166	CcSEcCtD
Paclitaxel—Convulsion—Doxorubicin—urinary bladder cancer	1.91e-05	0.000165	CcSEcCtD
Paclitaxel—Nervous system disorder—Epirubicin—urinary bladder cancer	1.91e-05	0.000165	CcSEcCtD
Paclitaxel—Thrombocytopenia—Epirubicin—urinary bladder cancer	1.9e-05	0.000165	CcSEcCtD
Paclitaxel—Hypertension—Doxorubicin—urinary bladder cancer	1.9e-05	0.000165	CcSEcCtD
Paclitaxel—Tachycardia—Epirubicin—urinary bladder cancer	1.9e-05	0.000164	CcSEcCtD
Paclitaxel—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	1.89e-05	0.000164	CcSEcCtD
Paclitaxel—Skin disorder—Epirubicin—urinary bladder cancer	1.89e-05	0.000164	CcSEcCtD
Paclitaxel—Hyperhidrosis—Epirubicin—urinary bladder cancer	1.88e-05	0.000163	CcSEcCtD
Paclitaxel—Insomnia—Methotrexate—urinary bladder cancer	1.88e-05	0.000163	CcSEcCtD
Paclitaxel—Chest pain—Doxorubicin—urinary bladder cancer	1.88e-05	0.000163	CcSEcCtD
Paclitaxel—Arthralgia—Doxorubicin—urinary bladder cancer	1.88e-05	0.000163	CcSEcCtD
Paclitaxel—Myalgia—Doxorubicin—urinary bladder cancer	1.88e-05	0.000163	CcSEcCtD
Paclitaxel—Anxiety—Doxorubicin—urinary bladder cancer	1.87e-05	0.000162	CcSEcCtD
Paclitaxel—Paraesthesia—Methotrexate—urinary bladder cancer	1.87e-05	0.000162	CcSEcCtD
Paclitaxel—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	1.86e-05	0.000161	CcSEcCtD
Paclitaxel—Discomfort—Doxorubicin—urinary bladder cancer	1.85e-05	0.000161	CcSEcCtD
Paclitaxel—Anorexia—Epirubicin—urinary bladder cancer	1.85e-05	0.000161	CcSEcCtD
Paclitaxel—Dyspnoea—Methotrexate—urinary bladder cancer	1.85e-05	0.00016	CcSEcCtD
Paclitaxel—Somnolence—Methotrexate—urinary bladder cancer	1.85e-05	0.00016	CcSEcCtD
Paclitaxel—Dry mouth—Doxorubicin—urinary bladder cancer	1.84e-05	0.000159	CcSEcCtD
Paclitaxel—Dyspepsia—Methotrexate—urinary bladder cancer	1.83e-05	0.000158	CcSEcCtD
Paclitaxel—Hypotension—Epirubicin—urinary bladder cancer	1.82e-05	0.000157	CcSEcCtD
Paclitaxel—Confusional state—Doxorubicin—urinary bladder cancer	1.81e-05	0.000157	CcSEcCtD
Paclitaxel—Decreased appetite—Methotrexate—urinary bladder cancer	1.81e-05	0.000156	CcSEcCtD
Paclitaxel—Anaphylactic shock—Doxorubicin—urinary bladder cancer	1.8e-05	0.000156	CcSEcCtD
Paclitaxel—Oedema—Doxorubicin—urinary bladder cancer	1.8e-05	0.000156	CcSEcCtD
Paclitaxel—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	1.79e-05	0.000155	CcSEcCtD
Paclitaxel—Fatigue—Methotrexate—urinary bladder cancer	1.79e-05	0.000155	CcSEcCtD
Paclitaxel—Infection—Doxorubicin—urinary bladder cancer	1.79e-05	0.000155	CcSEcCtD
Paclitaxel—Pain—Methotrexate—urinary bladder cancer	1.78e-05	0.000154	CcSEcCtD
Paclitaxel—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	1.77e-05	0.000153	CcSEcCtD
Paclitaxel—Shock—Doxorubicin—urinary bladder cancer	1.77e-05	0.000153	CcSEcCtD
Paclitaxel—Nervous system disorder—Doxorubicin—urinary bladder cancer	1.76e-05	0.000153	CcSEcCtD
Paclitaxel—Thrombocytopenia—Doxorubicin—urinary bladder cancer	1.76e-05	0.000153	CcSEcCtD
Paclitaxel—Insomnia—Epirubicin—urinary bladder cancer	1.76e-05	0.000152	CcSEcCtD
Paclitaxel—Tachycardia—Doxorubicin—urinary bladder cancer	1.76e-05	0.000152	CcSEcCtD
Paclitaxel—Skin disorder—Doxorubicin—urinary bladder cancer	1.75e-05	0.000151	CcSEcCtD
Paclitaxel—Paraesthesia—Epirubicin—urinary bladder cancer	1.75e-05	0.000151	CcSEcCtD
Paclitaxel—Hyperhidrosis—Doxorubicin—urinary bladder cancer	1.74e-05	0.000151	CcSEcCtD
Paclitaxel—Dyspnoea—Epirubicin—urinary bladder cancer	1.73e-05	0.00015	CcSEcCtD
Paclitaxel—Somnolence—Epirubicin—urinary bladder cancer	1.73e-05	0.00015	CcSEcCtD
Paclitaxel—Anorexia—Doxorubicin—urinary bladder cancer	1.72e-05	0.000149	CcSEcCtD
Paclitaxel—Feeling abnormal—Methotrexate—urinary bladder cancer	1.71e-05	0.000148	CcSEcCtD
Paclitaxel—Dyspepsia—Epirubicin—urinary bladder cancer	1.71e-05	0.000148	CcSEcCtD
Paclitaxel—Gastrointestinal pain—Methotrexate—urinary bladder cancer	1.7e-05	0.000147	CcSEcCtD
Paclitaxel—Decreased appetite—Epirubicin—urinary bladder cancer	1.69e-05	0.000146	CcSEcCtD
Paclitaxel—Hypotension—Doxorubicin—urinary bladder cancer	1.68e-05	0.000146	CcSEcCtD
Paclitaxel—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	1.68e-05	0.000145	CcSEcCtD
Paclitaxel—Fatigue—Epirubicin—urinary bladder cancer	1.68e-05	0.000145	CcSEcCtD
Paclitaxel—Pain—Epirubicin—urinary bladder cancer	1.66e-05	0.000144	CcSEcCtD
Paclitaxel—Constipation—Epirubicin—urinary bladder cancer	1.66e-05	0.000144	CcSEcCtD
Paclitaxel—Urticaria—Methotrexate—urinary bladder cancer	1.65e-05	0.000143	CcSEcCtD
Paclitaxel—Abdominal pain—Methotrexate—urinary bladder cancer	1.64e-05	0.000142	CcSEcCtD
Paclitaxel—Body temperature increased—Methotrexate—urinary bladder cancer	1.64e-05	0.000142	CcSEcCtD
Paclitaxel—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	1.64e-05	0.000142	CcSEcCtD
Paclitaxel—Insomnia—Doxorubicin—urinary bladder cancer	1.63e-05	0.000141	CcSEcCtD
Paclitaxel—Paraesthesia—Doxorubicin—urinary bladder cancer	1.62e-05	0.00014	CcSEcCtD
Paclitaxel—Dyspnoea—Doxorubicin—urinary bladder cancer	1.6e-05	0.000139	CcSEcCtD
Paclitaxel—Feeling abnormal—Epirubicin—urinary bladder cancer	1.6e-05	0.000139	CcSEcCtD
Paclitaxel—Somnolence—Doxorubicin—urinary bladder cancer	1.6e-05	0.000139	CcSEcCtD
Paclitaxel—Gastrointestinal pain—Epirubicin—urinary bladder cancer	1.59e-05	0.000138	CcSEcCtD
Paclitaxel—Dyspepsia—Doxorubicin—urinary bladder cancer	1.58e-05	0.000137	CcSEcCtD
Paclitaxel—Decreased appetite—Doxorubicin—urinary bladder cancer	1.56e-05	0.000135	CcSEcCtD
Paclitaxel—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	1.55e-05	0.000135	CcSEcCtD
Paclitaxel—Fatigue—Doxorubicin—urinary bladder cancer	1.55e-05	0.000134	CcSEcCtD
Paclitaxel—Urticaria—Epirubicin—urinary bladder cancer	1.54e-05	0.000134	CcSEcCtD
Paclitaxel—Pain—Doxorubicin—urinary bladder cancer	1.54e-05	0.000133	CcSEcCtD
Paclitaxel—Constipation—Doxorubicin—urinary bladder cancer	1.54e-05	0.000133	CcSEcCtD
Paclitaxel—Abdominal pain—Epirubicin—urinary bladder cancer	1.54e-05	0.000133	CcSEcCtD
Paclitaxel—Body temperature increased—Epirubicin—urinary bladder cancer	1.54e-05	0.000133	CcSEcCtD
Paclitaxel—Hypersensitivity—Methotrexate—urinary bladder cancer	1.53e-05	0.000133	CcSEcCtD
Paclitaxel—Asthenia—Methotrexate—urinary bladder cancer	1.49e-05	0.000129	CcSEcCtD
Paclitaxel—Feeling abnormal—Doxorubicin—urinary bladder cancer	1.48e-05	0.000128	CcSEcCtD
Paclitaxel—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	1.47e-05	0.000127	CcSEcCtD
Paclitaxel—Pruritus—Methotrexate—urinary bladder cancer	1.47e-05	0.000127	CcSEcCtD
Paclitaxel—Hypersensitivity—Epirubicin—urinary bladder cancer	1.43e-05	0.000124	CcSEcCtD
Paclitaxel—Urticaria—Doxorubicin—urinary bladder cancer	1.43e-05	0.000124	CcSEcCtD
Paclitaxel—Body temperature increased—Doxorubicin—urinary bladder cancer	1.42e-05	0.000123	CcSEcCtD
Paclitaxel—Abdominal pain—Doxorubicin—urinary bladder cancer	1.42e-05	0.000123	CcSEcCtD
Paclitaxel—Diarrhoea—Methotrexate—urinary bladder cancer	1.42e-05	0.000123	CcSEcCtD
Paclitaxel—Asthenia—Epirubicin—urinary bladder cancer	1.4e-05	0.000121	CcSEcCtD
Paclitaxel—Pruritus—Epirubicin—urinary bladder cancer	1.38e-05	0.000119	CcSEcCtD
Paclitaxel—Dizziness—Methotrexate—urinary bladder cancer	1.37e-05	0.000119	CcSEcCtD
Paclitaxel—Diarrhoea—Epirubicin—urinary bladder cancer	1.33e-05	0.000115	CcSEcCtD
Paclitaxel—Hypersensitivity—Doxorubicin—urinary bladder cancer	1.33e-05	0.000115	CcSEcCtD
Paclitaxel—Vomiting—Methotrexate—urinary bladder cancer	1.32e-05	0.000114	CcSEcCtD
Paclitaxel—Rash—Methotrexate—urinary bladder cancer	1.31e-05	0.000113	CcSEcCtD
Paclitaxel—Dermatitis—Methotrexate—urinary bladder cancer	1.31e-05	0.000113	CcSEcCtD
Paclitaxel—Headache—Methotrexate—urinary bladder cancer	1.3e-05	0.000113	CcSEcCtD
Paclitaxel—Asthenia—Doxorubicin—urinary bladder cancer	1.29e-05	0.000112	CcSEcCtD
Paclitaxel—Dizziness—Epirubicin—urinary bladder cancer	1.29e-05	0.000111	CcSEcCtD
Paclitaxel—Pruritus—Doxorubicin—urinary bladder cancer	1.27e-05	0.00011	CcSEcCtD
Paclitaxel—Vomiting—Epirubicin—urinary bladder cancer	1.24e-05	0.000107	CcSEcCtD
Paclitaxel—Nausea—Methotrexate—urinary bladder cancer	1.23e-05	0.000107	CcSEcCtD
Paclitaxel—Diarrhoea—Doxorubicin—urinary bladder cancer	1.23e-05	0.000107	CcSEcCtD
Paclitaxel—Rash—Epirubicin—urinary bladder cancer	1.23e-05	0.000106	CcSEcCtD
Paclitaxel—Dermatitis—Epirubicin—urinary bladder cancer	1.23e-05	0.000106	CcSEcCtD
Paclitaxel—Headache—Epirubicin—urinary bladder cancer	1.22e-05	0.000106	CcSEcCtD
Paclitaxel—Dizziness—Doxorubicin—urinary bladder cancer	1.19e-05	0.000103	CcSEcCtD
Paclitaxel—Nausea—Epirubicin—urinary bladder cancer	1.16e-05	0.0001	CcSEcCtD
Paclitaxel—Vomiting—Doxorubicin—urinary bladder cancer	1.14e-05	9.91e-05	CcSEcCtD
Paclitaxel—Rash—Doxorubicin—urinary bladder cancer	1.13e-05	9.83e-05	CcSEcCtD
Paclitaxel—Dermatitis—Doxorubicin—urinary bladder cancer	1.13e-05	9.82e-05	CcSEcCtD
Paclitaxel—Headache—Doxorubicin—urinary bladder cancer	1.13e-05	9.76e-05	CcSEcCtD
Paclitaxel—Nausea—Doxorubicin—urinary bladder cancer	1.07e-05	9.26e-05	CcSEcCtD
Paclitaxel—ABCB1—Metabolism—PRSS3—urinary bladder cancer	6.19e-06	9.86e-05	CbGpPWpGaD
Paclitaxel—NR1I2—Gene Expression—MYC—urinary bladder cancer	6.19e-06	9.85e-05	CbGpPWpGaD
Paclitaxel—ABCB11—Metabolism—NCOR1—urinary bladder cancer	6.19e-06	9.85e-05	CbGpPWpGaD
Paclitaxel—ABCB11—Metabolism—GSTM1—urinary bladder cancer	6.19e-06	9.85e-05	CbGpPWpGaD
Paclitaxel—SLCO1B3—Metabolism—ERCC2—urinary bladder cancer	6.18e-06	9.84e-05	CbGpPWpGaD
Paclitaxel—CYP19A1—Metabolism—NQO1—urinary bladder cancer	6.09e-06	9.7e-05	CbGpPWpGaD
Paclitaxel—ABCC1—Metabolism—NQO1—urinary bladder cancer	6.07e-06	9.66e-05	CbGpPWpGaD
Paclitaxel—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—urinary bladder cancer	6.06e-06	9.64e-05	CbGpPWpGaD
Paclitaxel—ABCG2—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	6.01e-06	9.57e-05	CbGpPWpGaD
Paclitaxel—CYP2C9—Metabolism—SLC19A1—urinary bladder cancer	5.94e-06	9.45e-05	CbGpPWpGaD
Paclitaxel—CYP3A5—Metabolism—NAT2—urinary bladder cancer	5.93e-06	9.45e-05	CbGpPWpGaD
Paclitaxel—ABCB11—Metabolism—GPX1—urinary bladder cancer	5.93e-06	9.43e-05	CbGpPWpGaD
Paclitaxel—CYP19A1—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	5.91e-06	9.41e-05	CbGpPWpGaD
Paclitaxel—ABCC1—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	5.89e-06	9.37e-05	CbGpPWpGaD
Paclitaxel—CYP1B1—Metabolism—NQO1—urinary bladder cancer	5.87e-06	9.34e-05	CbGpPWpGaD
Paclitaxel—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—urinary bladder cancer	5.86e-06	9.33e-05	CbGpPWpGaD
Paclitaxel—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—urinary bladder cancer	5.85e-06	9.31e-05	CbGpPWpGaD
Paclitaxel—ABCB11—Metabolism—ERCC2—urinary bladder cancer	5.82e-06	9.26e-05	CbGpPWpGaD
Paclitaxel—SLCO1B3—Metabolism—MTHFR—urinary bladder cancer	5.81e-06	9.25e-05	CbGpPWpGaD
Paclitaxel—CYP2C9—Metabolism—PRSS3—urinary bladder cancer	5.79e-06	9.21e-05	CbGpPWpGaD
Paclitaxel—CYP2C8—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	5.7e-06	9.07e-05	CbGpPWpGaD
Paclitaxel—CYP1B1—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	5.69e-06	9.06e-05	CbGpPWpGaD
Paclitaxel—TUBB4B—Cell Cycle—TP53—urinary bladder cancer	5.68e-06	9.05e-05	CbGpPWpGaD
Paclitaxel—CYP2C8—Metabolism—TYMP—urinary bladder cancer	5.68e-06	9.05e-05	CbGpPWpGaD
Paclitaxel—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—urinary bladder cancer	5.58e-06	8.88e-05	CbGpPWpGaD
Paclitaxel—ABCC1—Disease—NCOR1—urinary bladder cancer	5.55e-06	8.84e-05	CbGpPWpGaD
Paclitaxel—BCL2—Immune System—ERBB2—urinary bladder cancer	5.53e-06	8.8e-05	CbGpPWpGaD
Paclitaxel—ABCB11—Metabolism—MTHFR—urinary bladder cancer	5.47e-06	8.71e-05	CbGpPWpGaD
Paclitaxel—CYP2C8—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	5.46e-06	8.69e-05	CbGpPWpGaD
Paclitaxel—ABCB1—Integrated Pancreatic Cancer Pathway—SRC—urinary bladder cancer	5.42e-06	8.63e-05	CbGpPWpGaD
Paclitaxel—ABCG2—Metabolism—NQO1—urinary bladder cancer	5.34e-06	8.5e-05	CbGpPWpGaD
Paclitaxel—CYP3A4—Metabolism—GSTZ1—urinary bladder cancer	5.31e-06	8.46e-05	CbGpPWpGaD
Paclitaxel—CYP3A7—Metabolism—NQO1—urinary bladder cancer	5.29e-06	8.42e-05	CbGpPWpGaD
Paclitaxel—BCL2—Innate Immune System—HRAS—urinary bladder cancer	5.28e-06	8.41e-05	CbGpPWpGaD
Paclitaxel—ABCC1—Disease—ERCC2—urinary bladder cancer	5.22e-06	8.31e-05	CbGpPWpGaD
Paclitaxel—CYP19A1—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	5.16e-06	8.21e-05	CbGpPWpGaD
Paclitaxel—CYP2C8—Metabolism—NAT2—urinary bladder cancer	5.14e-06	8.18e-05	CbGpPWpGaD
Paclitaxel—ABCC1—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	5.13e-06	8.17e-05	CbGpPWpGaD
Paclitaxel—CYP3A5—Metabolism—RRM2—urinary bladder cancer	5.12e-06	8.15e-05	CbGpPWpGaD
Paclitaxel—CYP19A1—Metabolism—GSTP1—urinary bladder cancer	5.08e-06	8.09e-05	CbGpPWpGaD
Paclitaxel—ABCC1—Metabolism—GSTP1—urinary bladder cancer	5.06e-06	8.05e-05	CbGpPWpGaD
Paclitaxel—CYP3A4—Metabolism—GSTO2—urinary bladder cancer	5.04e-06	8.02e-05	CbGpPWpGaD
Paclitaxel—CYP3A4—Metabolism—NAT1—urinary bladder cancer	5.04e-06	8.02e-05	CbGpPWpGaD
Paclitaxel—BCL2—Immune System—IL2—urinary bladder cancer	5.01e-06	7.97e-05	CbGpPWpGaD
Paclitaxel—CYP1B1—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	4.96e-06	7.9e-05	CbGpPWpGaD
Paclitaxel—ABCB1—Metabolism—TYMP—urinary bladder cancer	4.95e-06	7.88e-05	CbGpPWpGaD
Paclitaxel—CYP19A1—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	4.92e-06	7.83e-05	CbGpPWpGaD
Paclitaxel—ABCC1—Disease—MTHFR—urinary bladder cancer	4.91e-06	7.81e-05	CbGpPWpGaD
Paclitaxel—ABCC1—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	4.89e-06	7.79e-05	CbGpPWpGaD
Paclitaxel—CYP1B1—Metabolism—GSTP1—urinary bladder cancer	4.89e-06	7.79e-05	CbGpPWpGaD
Paclitaxel—ABCC1—Disease—TERT—urinary bladder cancer	4.89e-06	7.79e-05	CbGpPWpGaD
Paclitaxel—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—urinary bladder cancer	4.86e-06	7.74e-05	CbGpPWpGaD
Paclitaxel—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—urinary bladder cancer	4.75e-06	7.57e-05	CbGpPWpGaD
Paclitaxel—CYP3A5—Metabolism—HPGDS—urinary bladder cancer	4.74e-06	7.55e-05	CbGpPWpGaD
Paclitaxel—CYP3A5—Metabolism—ENO2—urinary bladder cancer	4.74e-06	7.55e-05	CbGpPWpGaD
Paclitaxel—CYP1B1—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	4.73e-06	7.54e-05	CbGpPWpGaD
Paclitaxel—CYP19A1—Metabolism—TYMS—urinary bladder cancer	4.72e-06	7.52e-05	CbGpPWpGaD
Paclitaxel—BCL2—Immune System—CDKN1A—urinary bladder cancer	4.72e-06	7.52e-05	CbGpPWpGaD
Paclitaxel—BCL2—Immune System—PTEN—urinary bladder cancer	4.71e-06	7.5e-05	CbGpPWpGaD
Paclitaxel—SLCO1B3—Metabolism—PPARG—urinary bladder cancer	4.71e-06	7.5e-05	CbGpPWpGaD
Paclitaxel—ABCC1—Metabolism—TYMS—urinary bladder cancer	4.7e-06	7.49e-05	CbGpPWpGaD
Paclitaxel—CYP19A1—Metabolism—NCOR1—urinary bladder cancer	4.67e-06	7.43e-05	CbGpPWpGaD
Paclitaxel—CYP19A1—Metabolism—GSTM1—urinary bladder cancer	4.67e-06	7.43e-05	CbGpPWpGaD
Paclitaxel—ABCC1—Metabolism—GSTM1—urinary bladder cancer	4.65e-06	7.4e-05	CbGpPWpGaD
Paclitaxel—ABCC1—Metabolism—NCOR1—urinary bladder cancer	4.65e-06	7.4e-05	CbGpPWpGaD
Paclitaxel—CYP2C9—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	4.64e-06	7.39e-05	CbGpPWpGaD
Paclitaxel—CYP2C9—Metabolism—TYMP—urinary bladder cancer	4.63e-06	7.36e-05	CbGpPWpGaD
Paclitaxel—CYP3A4—Metabolism—UGT2B7—urinary bladder cancer	4.61e-06	7.33e-05	CbGpPWpGaD
Paclitaxel—CYP3A5—Metabolism—GSTT1—urinary bladder cancer	4.6e-06	7.32e-05	CbGpPWpGaD
Paclitaxel—CYP1B1—Metabolism—TYMS—urinary bladder cancer	4.55e-06	7.24e-05	CbGpPWpGaD
Paclitaxel—SLCO1B3—Metabolism—CREBBP—urinary bladder cancer	4.53e-06	7.21e-05	CbGpPWpGaD
Paclitaxel—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	4.53e-06	7.21e-05	CbGpPWpGaD
Paclitaxel—CYP1B1—Metabolism—GSTM1—urinary bladder cancer	4.5e-06	7.16e-05	CbGpPWpGaD
Paclitaxel—CYP1B1—Metabolism—NCOR1—urinary bladder cancer	4.5e-06	7.16e-05	CbGpPWpGaD
Paclitaxel—BCL2—Immune System—EP300—urinary bladder cancer	4.49e-06	7.15e-05	CbGpPWpGaD
Paclitaxel—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	4.49e-06	7.15e-05	CbGpPWpGaD
Paclitaxel—ABCC1—Disease—FGFR3—urinary bladder cancer	4.49e-06	7.15e-05	CbGpPWpGaD
Paclitaxel—ABCB1—Metabolism—NAT2—urinary bladder cancer	4.48e-06	7.13e-05	CbGpPWpGaD
Paclitaxel—CYP19A1—Metabolism—GPX1—urinary bladder cancer	4.47e-06	7.12e-05	CbGpPWpGaD
Paclitaxel—ABCC1—Metabolism—GPX1—urinary bladder cancer	4.45e-06	7.09e-05	CbGpPWpGaD
Paclitaxel—ABCG2—Metabolism—GSTP1—urinary bladder cancer	4.45e-06	7.09e-05	CbGpPWpGaD
Paclitaxel—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	4.44e-06	7.07e-05	CbGpPWpGaD
Paclitaxel—CYP2C8—Metabolism—RRM2—urinary bladder cancer	4.44e-06	7.06e-05	CbGpPWpGaD
Paclitaxel—ABCB11—Metabolism—PPARG—urinary bladder cancer	4.44e-06	7.06e-05	CbGpPWpGaD
Paclitaxel—CYP3A7—Metabolism—GSTP1—urinary bladder cancer	4.41e-06	7.02e-05	CbGpPWpGaD
Paclitaxel—CYP19A1—Metabolism—ERCC2—urinary bladder cancer	4.39e-06	6.99e-05	CbGpPWpGaD
Paclitaxel—ABCC1—Metabolism—ERCC2—urinary bladder cancer	4.37e-06	6.96e-05	CbGpPWpGaD
Paclitaxel—BCL2—Immune System—SRC—urinary bladder cancer	4.37e-06	6.96e-05	CbGpPWpGaD
Paclitaxel—CYP1B1—Metabolism—GPX1—urinary bladder cancer	4.31e-06	6.85e-05	CbGpPWpGaD
Paclitaxel—ABCB11—Metabolism—CREBBP—urinary bladder cancer	4.26e-06	6.78e-05	CbGpPWpGaD
Paclitaxel—CYP1B1—Metabolism—ERCC2—urinary bladder cancer	4.23e-06	6.73e-05	CbGpPWpGaD
Paclitaxel—CYP2C9—Metabolism—NAT2—urinary bladder cancer	4.18e-06	6.66e-05	CbGpPWpGaD
Paclitaxel—CYP3A4—Metabolism—CYP4B1—urinary bladder cancer	4.15e-06	6.6e-05	CbGpPWpGaD
Paclitaxel—ABCG2—Metabolism—TYMS—urinary bladder cancer	4.14e-06	6.59e-05	CbGpPWpGaD
Paclitaxel—CYP19A1—Metabolism—MTHFR—urinary bladder cancer	4.13e-06	6.57e-05	CbGpPWpGaD
Paclitaxel—CYP2C8—Metabolism—ENO2—urinary bladder cancer	4.11e-06	6.54e-05	CbGpPWpGaD
Paclitaxel—CYP2C8—Metabolism—HPGDS—urinary bladder cancer	4.11e-06	6.54e-05	CbGpPWpGaD
Paclitaxel—ABCC1—Metabolism—MTHFR—urinary bladder cancer	4.11e-06	6.54e-05	CbGpPWpGaD
Paclitaxel—CYP3A7—Metabolism—TYMS—urinary bladder cancer	4.1e-06	6.53e-05	CbGpPWpGaD
Paclitaxel—ABCG2—Metabolism—NCOR1—urinary bladder cancer	4.09e-06	6.51e-05	CbGpPWpGaD
Paclitaxel—ABCG2—Metabolism—GSTM1—urinary bladder cancer	4.09e-06	6.51e-05	CbGpPWpGaD
Paclitaxel—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	4.09e-06	6.5e-05	CbGpPWpGaD
Paclitaxel—CYP3A7—Metabolism—NCOR1—urinary bladder cancer	4.06e-06	6.45e-05	CbGpPWpGaD
Paclitaxel—CYP3A7—Metabolism—GSTM1—urinary bladder cancer	4.06e-06	6.45e-05	CbGpPWpGaD
Paclitaxel—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	3.99e-06	6.35e-05	CbGpPWpGaD
Paclitaxel—CYP2C8—Metabolism—GSTT1—urinary bladder cancer	3.99e-06	6.34e-05	CbGpPWpGaD
Paclitaxel—CYP1B1—Metabolism—MTHFR—urinary bladder cancer	3.97e-06	6.33e-05	CbGpPWpGaD
Paclitaxel—CYP2C8—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	3.92e-06	6.25e-05	CbGpPWpGaD
Paclitaxel—ABCG2—Metabolism—GPX1—urinary bladder cancer	3.92e-06	6.24e-05	CbGpPWpGaD
Paclitaxel—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	3.92e-06	6.23e-05	CbGpPWpGaD
Paclitaxel—CYP3A7—Metabolism—GPX1—urinary bladder cancer	3.88e-06	6.18e-05	CbGpPWpGaD
Paclitaxel—ABCB1—Metabolism—RRM2—urinary bladder cancer	3.87e-06	6.15e-05	CbGpPWpGaD
Paclitaxel—ABCG2—Metabolism—ERCC2—urinary bladder cancer	3.85e-06	6.12e-05	CbGpPWpGaD
Paclitaxel—BCL2—Immune System—EGFR—urinary bladder cancer	3.83e-06	6.1e-05	CbGpPWpGaD
Paclitaxel—CYP3A5—Metabolism—NQO1—urinary bladder cancer	3.82e-06	6.09e-05	CbGpPWpGaD
Paclitaxel—ABCC1—Disease—CREBBP—urinary bladder cancer	3.82e-06	6.08e-05	CbGpPWpGaD
Paclitaxel—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	3.82e-06	6.07e-05	CbGpPWpGaD
Paclitaxel—CYP3A7—Metabolism—ERCC2—urinary bladder cancer	3.81e-06	6.07e-05	CbGpPWpGaD
Paclitaxel—SLCO1B3—Metabolism—PTGS2—urinary bladder cancer	3.71e-06	5.9e-05	CbGpPWpGaD
Paclitaxel—BCL2—Immune System—KRAS—urinary bladder cancer	3.62e-06	5.76e-05	CbGpPWpGaD
Paclitaxel—ABCG2—Metabolism—MTHFR—urinary bladder cancer	3.62e-06	5.76e-05	CbGpPWpGaD
Paclitaxel—CYP2C9—Metabolism—RRM2—urinary bladder cancer	3.61e-06	5.75e-05	CbGpPWpGaD
Paclitaxel—CYP3A7—Metabolism—MTHFR—urinary bladder cancer	3.58e-06	5.7e-05	CbGpPWpGaD
Paclitaxel—ABCB1—Metabolism—ENO2—urinary bladder cancer	3.58e-06	5.7e-05	CbGpPWpGaD
Paclitaxel—ABCB1—Metabolism—HPGDS—urinary bladder cancer	3.58e-06	5.7e-05	CbGpPWpGaD
Paclitaxel—ABCB11—Metabolism—PTGS2—urinary bladder cancer	3.49e-06	5.55e-05	CbGpPWpGaD
Paclitaxel—ABCB1—Metabolism—GSTT1—urinary bladder cancer	3.47e-06	5.53e-05	CbGpPWpGaD
Paclitaxel—ABCC1—Disease—RHOA—urinary bladder cancer	3.46e-06	5.5e-05	CbGpPWpGaD
Paclitaxel—CYP19A1—Metabolism—PPARG—urinary bladder cancer	3.35e-06	5.33e-05	CbGpPWpGaD
Paclitaxel—CYP2C9—Metabolism—HPGDS—urinary bladder cancer	3.34e-06	5.32e-05	CbGpPWpGaD
Paclitaxel—CYP2C9—Metabolism—ENO2—urinary bladder cancer	3.34e-06	5.32e-05	CbGpPWpGaD
Paclitaxel—ABCC1—Metabolism—PPARG—urinary bladder cancer	3.33e-06	5.3e-05	CbGpPWpGaD
Paclitaxel—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	3.33e-06	5.29e-05	CbGpPWpGaD
Paclitaxel—CYP2C8—Metabolism—NQO1—urinary bladder cancer	3.31e-06	5.27e-05	CbGpPWpGaD
Paclitaxel—ABCB1—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	3.25e-06	5.17e-05	CbGpPWpGaD
Paclitaxel—CYP2C9—Metabolism—GSTT1—urinary bladder cancer	3.24e-06	5.16e-05	CbGpPWpGaD
Paclitaxel—SLCO1B3—Metabolism—PTEN—urinary bladder cancer	3.23e-06	5.15e-05	CbGpPWpGaD
Paclitaxel—CYP1B1—Metabolism—PPARG—urinary bladder cancer	3.22e-06	5.13e-05	CbGpPWpGaD
Paclitaxel—CYP19A1—Metabolism—CREBBP—urinary bladder cancer	3.21e-06	5.12e-05	CbGpPWpGaD
Paclitaxel—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	3.21e-06	5.12e-05	CbGpPWpGaD
Paclitaxel—ABCC1—Metabolism—CREBBP—urinary bladder cancer	3.2e-06	5.09e-05	CbGpPWpGaD
Paclitaxel—ABCC1—Disease—ERBB2—urinary bladder cancer	3.2e-06	5.09e-05	CbGpPWpGaD
Paclitaxel—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	3.19e-06	5.08e-05	CbGpPWpGaD
Paclitaxel—CYP3A5—Metabolism—GSTP1—urinary bladder cancer	3.19e-06	5.08e-05	CbGpPWpGaD
Paclitaxel—ABCC1—Disease—PTGS2—urinary bladder cancer	3.13e-06	4.98e-05	CbGpPWpGaD
Paclitaxel—CYP1B1—Metabolism—CREBBP—urinary bladder cancer	3.1e-06	4.93e-05	CbGpPWpGaD
Paclitaxel—SLCO1B3—Metabolism—EP300—urinary bladder cancer	3.08e-06	4.91e-05	CbGpPWpGaD
Paclitaxel—BCL2—Immune System—HRAS—urinary bladder cancer	3.08e-06	4.9e-05	CbGpPWpGaD
Paclitaxel—CYP3A4—Metabolism—TYMP—urinary bladder cancer	3.05e-06	4.86e-05	CbGpPWpGaD
Paclitaxel—ABCB11—Metabolism—PTEN—urinary bladder cancer	3.04e-06	4.84e-05	CbGpPWpGaD
Paclitaxel—CYP3A5—Metabolism—TYMS—urinary bladder cancer	2.97e-06	4.72e-05	CbGpPWpGaD
Paclitaxel—ABCG2—Metabolism—PPARG—urinary bladder cancer	2.93e-06	4.67e-05	CbGpPWpGaD
Paclitaxel—CYP3A5—Metabolism—GSTM1—urinary bladder cancer	2.93e-06	4.67e-05	CbGpPWpGaD
Paclitaxel—CYP3A5—Metabolism—NCOR1—urinary bladder cancer	2.93e-06	4.67e-05	CbGpPWpGaD
Paclitaxel—CYP3A7—Metabolism—PPARG—urinary bladder cancer	2.91e-06	4.63e-05	CbGpPWpGaD
Paclitaxel—ABCB11—Metabolism—EP300—urinary bladder cancer	2.9e-06	4.62e-05	CbGpPWpGaD
Paclitaxel—ABCB1—Metabolism—NQO1—urinary bladder cancer	2.89e-06	4.59e-05	CbGpPWpGaD
Paclitaxel—ABCG2—Metabolism—CREBBP—urinary bladder cancer	2.82e-06	4.48e-05	CbGpPWpGaD
Paclitaxel—CYP3A5—Metabolism—GPX1—urinary bladder cancer	2.81e-06	4.47e-05	CbGpPWpGaD
Paclitaxel—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	2.8e-06	4.46e-05	CbGpPWpGaD
Paclitaxel—CYP3A7—Metabolism—CREBBP—urinary bladder cancer	2.79e-06	4.44e-05	CbGpPWpGaD
Paclitaxel—CYP2C8—Metabolism—GSTP1—urinary bladder cancer	2.76e-06	4.4e-05	CbGpPWpGaD
Paclitaxel—CYP3A4—Metabolism—NAT2—urinary bladder cancer	2.76e-06	4.39e-05	CbGpPWpGaD
Paclitaxel—CYP3A5—Metabolism—ERCC2—urinary bladder cancer	2.76e-06	4.39e-05	CbGpPWpGaD
Paclitaxel—ABCC1—Disease—CDKN1A—urinary bladder cancer	2.74e-06	4.35e-05	CbGpPWpGaD
Paclitaxel—ABCC1—Disease—PTEN—urinary bladder cancer	2.73e-06	4.34e-05	CbGpPWpGaD
Paclitaxel—CYP2C9—Metabolism—NQO1—urinary bladder cancer	2.7e-06	4.29e-05	CbGpPWpGaD
Paclitaxel—CYP2C8—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	2.67e-06	4.25e-05	CbGpPWpGaD
Paclitaxel—CYP19A1—Metabolism—PTGS2—urinary bladder cancer	2.63e-06	4.19e-05	CbGpPWpGaD
Paclitaxel—ABCC1—Metabolism—PTGS2—urinary bladder cancer	2.62e-06	4.17e-05	CbGpPWpGaD
Paclitaxel—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	2.62e-06	4.16e-05	CbGpPWpGaD
Paclitaxel—ABCC1—Disease—EP300—urinary bladder cancer	2.6e-06	4.14e-05	CbGpPWpGaD
Paclitaxel—CYP3A5—Metabolism—MTHFR—urinary bladder cancer	2.59e-06	4.12e-05	CbGpPWpGaD
Paclitaxel—CYP2C8—Metabolism—TYMS—urinary bladder cancer	2.57e-06	4.09e-05	CbGpPWpGaD
Paclitaxel—CYP2C8—Metabolism—GSTM1—urinary bladder cancer	2.54e-06	4.04e-05	CbGpPWpGaD
Paclitaxel—CYP2C8—Metabolism—NCOR1—urinary bladder cancer	2.54e-06	4.04e-05	CbGpPWpGaD
Paclitaxel—CYP1B1—Metabolism—PTGS2—urinary bladder cancer	2.54e-06	4.04e-05	CbGpPWpGaD
Paclitaxel—ABCC1—Disease—SRC—urinary bladder cancer	2.53e-06	4.03e-05	CbGpPWpGaD
Paclitaxel—CYP2C8—Metabolism—GPX1—urinary bladder cancer	2.43e-06	3.87e-05	CbGpPWpGaD
Paclitaxel—ABCB1—Metabolism—GSTP1—urinary bladder cancer	2.41e-06	3.83e-05	CbGpPWpGaD
Paclitaxel—CYP2C8—Metabolism—ERCC2—urinary bladder cancer	2.39e-06	3.8e-05	CbGpPWpGaD
Paclitaxel—CYP3A4—Metabolism—RRM2—urinary bladder cancer	2.38e-06	3.79e-05	CbGpPWpGaD
Paclitaxel—ABCG2—Metabolism—PTGS2—urinary bladder cancer	2.31e-06	3.67e-05	CbGpPWpGaD
Paclitaxel—CYP19A1—Metabolism—PTEN—urinary bladder cancer	2.3e-06	3.65e-05	CbGpPWpGaD
Paclitaxel—CYP3A7—Metabolism—PTGS2—urinary bladder cancer	2.29e-06	3.64e-05	CbGpPWpGaD
Paclitaxel—ABCC1—Metabolism—PTEN—urinary bladder cancer	2.29e-06	3.64e-05	CbGpPWpGaD
Paclitaxel—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	2.28e-06	3.63e-05	CbGpPWpGaD
Paclitaxel—ABCC1—Disease—MYC—urinary bladder cancer	2.27e-06	3.61e-05	CbGpPWpGaD
Paclitaxel—CYP2C9—Metabolism—GSTP1—urinary bladder cancer	2.25e-06	3.58e-05	CbGpPWpGaD
Paclitaxel—CYP2C8—Metabolism—MTHFR—urinary bladder cancer	2.24e-06	3.57e-05	CbGpPWpGaD
Paclitaxel—ABCB1—Metabolism—TYMS—urinary bladder cancer	2.24e-06	3.56e-05	CbGpPWpGaD
Paclitaxel—ABCC1—Disease—EGFR—urinary bladder cancer	2.22e-06	3.53e-05	CbGpPWpGaD
Paclitaxel—ABCB1—Metabolism—NCOR1—urinary bladder cancer	2.21e-06	3.52e-05	CbGpPWpGaD
Paclitaxel—ABCB1—Metabolism—GSTM1—urinary bladder cancer	2.21e-06	3.52e-05	CbGpPWpGaD
Paclitaxel—CYP1B1—Metabolism—PTEN—urinary bladder cancer	2.21e-06	3.52e-05	CbGpPWpGaD
Paclitaxel—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	2.21e-06	3.51e-05	CbGpPWpGaD
Paclitaxel—CYP3A4—Metabolism—ENO2—urinary bladder cancer	2.21e-06	3.51e-05	CbGpPWpGaD
Paclitaxel—CYP19A1—Metabolism—EP300—urinary bladder cancer	2.19e-06	3.49e-05	CbGpPWpGaD
Paclitaxel—ABCC1—Metabolism—EP300—urinary bladder cancer	2.18e-06	3.47e-05	CbGpPWpGaD
Paclitaxel—CYP2C9—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	2.18e-06	3.46e-05	CbGpPWpGaD
Paclitaxel—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	2.14e-06	3.41e-05	CbGpPWpGaD
Paclitaxel—ABCB1—Metabolism—GPX1—urinary bladder cancer	2.12e-06	3.37e-05	CbGpPWpGaD
Paclitaxel—CYP1B1—Metabolism—EP300—urinary bladder cancer	2.11e-06	3.36e-05	CbGpPWpGaD
Paclitaxel—CYP3A5—Metabolism—PPARG—urinary bladder cancer	2.1e-06	3.34e-05	CbGpPWpGaD
Paclitaxel—ABCC1—Disease—KRAS—urinary bladder cancer	2.1e-06	3.34e-05	CbGpPWpGaD
Paclitaxel—CYP2C9—Metabolism—TYMS—urinary bladder cancer	2.09e-06	3.33e-05	CbGpPWpGaD
Paclitaxel—ABCB1—Metabolism—ERCC2—urinary bladder cancer	2.08e-06	3.31e-05	CbGpPWpGaD
Paclitaxel—CYP2C9—Metabolism—GSTM1—urinary bladder cancer	2.07e-06	3.29e-05	CbGpPWpGaD
Paclitaxel—CYP2C9—Metabolism—NCOR1—urinary bladder cancer	2.07e-06	3.29e-05	CbGpPWpGaD
Paclitaxel—CYP3A5—Metabolism—CREBBP—urinary bladder cancer	2.02e-06	3.21e-05	CbGpPWpGaD
Paclitaxel—ABCG2—Metabolism—PTEN—urinary bladder cancer	2.01e-06	3.2e-05	CbGpPWpGaD
Paclitaxel—CYP3A7—Metabolism—PTEN—urinary bladder cancer	1.99e-06	3.17e-05	CbGpPWpGaD
Paclitaxel—CYP2C9—Metabolism—GPX1—urinary bladder cancer	1.98e-06	3.15e-05	CbGpPWpGaD
Paclitaxel—ABCB1—Metabolism—MTHFR—urinary bladder cancer	1.95e-06	3.11e-05	CbGpPWpGaD
Paclitaxel—CYP2C9—Metabolism—ERCC2—urinary bladder cancer	1.94e-06	3.09e-05	CbGpPWpGaD
Paclitaxel—ABCG2—Metabolism—EP300—urinary bladder cancer	1.92e-06	3.05e-05	CbGpPWpGaD
Paclitaxel—CYP3A7—Metabolism—EP300—urinary bladder cancer	1.9e-06	3.03e-05	CbGpPWpGaD
Paclitaxel—CYP2C9—Metabolism—MTHFR—urinary bladder cancer	1.83e-06	2.91e-05	CbGpPWpGaD
Paclitaxel—CYP2C8—Metabolism—PPARG—urinary bladder cancer	1.82e-06	2.9e-05	CbGpPWpGaD
Paclitaxel—ABCC1—Disease—HRAS—urinary bladder cancer	1.78e-06	2.84e-05	CbGpPWpGaD
Paclitaxel—CYP3A4—Metabolism—NQO1—urinary bladder cancer	1.78e-06	2.83e-05	CbGpPWpGaD
Paclitaxel—CYP2C8—Metabolism—CREBBP—urinary bladder cancer	1.75e-06	2.78e-05	CbGpPWpGaD
Paclitaxel—CYP3A5—Metabolism—PTGS2—urinary bladder cancer	1.65e-06	2.63e-05	CbGpPWpGaD
Paclitaxel—ABCB1—Metabolism—PPARG—urinary bladder cancer	1.59e-06	2.52e-05	CbGpPWpGaD
Paclitaxel—ABCB1—Metabolism—CREBBP—urinary bladder cancer	1.52e-06	2.42e-05	CbGpPWpGaD
Paclitaxel—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	1.48e-06	2.36e-05	CbGpPWpGaD
Paclitaxel—CYP2C9—Metabolism—PPARG—urinary bladder cancer	1.48e-06	2.36e-05	CbGpPWpGaD
Paclitaxel—CYP3A5—Metabolism—PTEN—urinary bladder cancer	1.44e-06	2.29e-05	CbGpPWpGaD
Paclitaxel—CYP2C8—Metabolism—PTGS2—urinary bladder cancer	1.43e-06	2.28e-05	CbGpPWpGaD
Paclitaxel—CYP2C9—Metabolism—CREBBP—urinary bladder cancer	1.42e-06	2.26e-05	CbGpPWpGaD
Paclitaxel—CYP3A4—Metabolism—TYMS—urinary bladder cancer	1.38e-06	2.19e-05	CbGpPWpGaD
Paclitaxel—CYP3A5—Metabolism—EP300—urinary bladder cancer	1.37e-06	2.19e-05	CbGpPWpGaD
Paclitaxel—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	1.36e-06	2.17e-05	CbGpPWpGaD
Paclitaxel—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	1.36e-06	2.17e-05	CbGpPWpGaD
Paclitaxel—CYP3A4—Metabolism—GPX1—urinary bladder cancer	1.31e-06	2.08e-05	CbGpPWpGaD
Paclitaxel—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	1.28e-06	2.04e-05	CbGpPWpGaD
Paclitaxel—CYP2C8—Metabolism—PTEN—urinary bladder cancer	1.25e-06	1.99e-05	CbGpPWpGaD
Paclitaxel—ABCB1—Metabolism—PTGS2—urinary bladder cancer	1.25e-06	1.98e-05	CbGpPWpGaD
Paclitaxel—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	1.2e-06	1.92e-05	CbGpPWpGaD
Paclitaxel—CYP2C8—Metabolism—EP300—urinary bladder cancer	1.19e-06	1.89e-05	CbGpPWpGaD
Paclitaxel—CYP2C9—Metabolism—PTGS2—urinary bladder cancer	1.16e-06	1.85e-05	CbGpPWpGaD
Paclitaxel—ABCB1—Metabolism—PTEN—urinary bladder cancer	1.09e-06	1.73e-05	CbGpPWpGaD
Paclitaxel—ABCB1—Metabolism—EP300—urinary bladder cancer	1.04e-06	1.65e-05	CbGpPWpGaD
Paclitaxel—CYP2C9—Metabolism—PTEN—urinary bladder cancer	1.02e-06	1.62e-05	CbGpPWpGaD
Paclitaxel—CYP3A4—Metabolism—PPARG—urinary bladder cancer	9.77e-07	1.55e-05	CbGpPWpGaD
Paclitaxel—CYP2C9—Metabolism—EP300—urinary bladder cancer	9.69e-07	1.54e-05	CbGpPWpGaD
Paclitaxel—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	9.38e-07	1.49e-05	CbGpPWpGaD
Paclitaxel—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	7.68e-07	1.22e-05	CbGpPWpGaD
Paclitaxel—CYP3A4—Metabolism—PTEN—urinary bladder cancer	6.7e-07	1.07e-05	CbGpPWpGaD
Paclitaxel—CYP3A4—Metabolism—EP300—urinary bladder cancer	6.39e-07	1.02e-05	CbGpPWpGaD
